Autoinjectors is revolutionizing medicine delivery. Over the years, the incidence of various chronic diseases, such as diabetes, multiple sclerosis and rheumatoid arthritis, have increased at significant rates; these chronic conditions often require regular and precise administration of medications, necessitating the need for user-friendly and self-administration devices.

The global autoinjectors market size is estimated to be worth USD 96.2 billion in 2025 and is projected to reach USD 176 billion by the year 2035, growing at a CAGR of 6.2% during the forecast period, till 2035.

Further, the pandemic enhanced the focus on remote healthcare solutions, leading to a significant increase in the adoption of self-injection devices (in order to reduce hospital visits of individuals and make them incharge of managing their health from the comfort of their homes). Among the various patient-centric solutions, autoinjectors have gained prominence in the healthcare domain. Autoinjectors are self-injection devices that automatically insert the needle and deliver a specific dose of a drug / therapeutic substance, typically via a spring driven mechanism. They are generally used in combination with primary containers, such as prefilled syringes and administer the drugs primarily through subcutaneous or intramuscular route.

It is worth mentioning that autoinjector manufacturers are continuously driving innovation in autoinjector technology by incorporating smart features and connectivity (including Bluetooth connectivity and companion apps), developing platform products and modular designs (easily customizable for each drug) and expanding the use of autoinjectors for new therapeutic areas (including autoimmune diseases and oncology).

The current market landscape features the presence of close to 150 autoinjectors (being manufactured by over 50 players), that are currently available / under development for the treatment of various target indications. The autoinjectors market is highly fragmented, featuring the presence of established firms as well as emerging start-ups. Majority of the companies engaged in this domain are headquartered in North America; within this region, over 90% of the companies are headquartered in the US, while around 10% are located in Canada. This can be attributed to the fact that the US offers a robust pharmaceutical market, along with supportive regulatory framework for medical device manufacturers, making it an attractive hub for autoinjector manufacturers. This is closely followed by players based in Europe (specifically in the UK and Switzerland).

Majority (~85%) of the autoinjectors are commercialized; of these, over 45% are designed for single use (can be discarded after one use). Some advantages of disposable autoinjectors  include convenient use, requirement of minimal training, elimination of the need for refilling after each use and a preferred option for patients with limited dexterity and mobility. Further, most (80%) of the autoinjectors are equipped with both audible and visual indicators, which help the users confirm correct activation and usage of device, and maintain a controlled and secured injection process. Notably, majority of the autoinjectors are intended to deliver peptides (for the treatment of autoimmune disorders, cardiovascular disorders and genetic disorders).

Research Methodology

Our analysts have performed an accurate examination of the various aspects of the global market leveraging avant-garde primary and secondary sources of data collection. The report has gathered the necessary data and information from several reliable sources. Additionally, the report offers many strategic recommendations for companies involved in this ever-growing business sector to help them attain a competitive edge in the Autoinjectors Market.

Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs. 

To view more details on this report, click on the link
https://www.rootsanalysis.com/reports/autoinjectors-market/293.html

About Roots Analysis

Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.

Contact:

Roots Analysis

+1 (415) 800 3415

[email protected]